Clinical Trial Detail

NCT ID NCT02469415
Title Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

bone marrow cancer

Therapies

Decitabine

Azacitidine

Pacritinib

Age Groups: adult

No variant requirements are available.